| RESERVED AREA | LANGUAGE

Lung Cancer Study Group

(Português) home-2022

N E W S

MEN-MADE-CANCER-2022

Men Made Cancer

Men Made Cancer: “Lung cancer is the biggest killer, but its main risk factors are modifiable” “Men Made Cancer” is the motto of the new campaign by the Lung Cancer Study Group (GECP) for World Lung Cancer Day, which is…

Tecentriq (atezolizumab) gets Infarmed approval for new indications

Tecentriq (atezolizumab) gets Infarmed approval for new indications

The drug Tecentriq (atezolizumab) obtained authorization from the National Authority for Medicines and Health Products (Infarmed) to be used in hospitals in new indications for the treatment of lung cancer. According to the grant recently published on the Infarmed website,…

artigo_escolhido_gecp_14julho2022

Chosen Article

Dr. Fernanda EstevinhoOncologist at Hospital Pedro Hispano – ULS MatosinhosSelected Article: “Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data” O artigo selecionado…

Today marks World Social Media Day

Today marks World Social Media Day

To celebrate this anniversary, we recall the GECP’s journey through the most used digital communication networks around the world.After our debut on Facebook and Instagram in May 2020, we created an institutional page on LinkedIn last year.At a time when…

World No Tobacco Day

World No Tobacco Day

Lung cancer is more than smoking” is the motto of the GECP campaign to mark the World No Tobacco Day, which is celebrated annually on the 31st of May.Today we focus on demystifying the stigma associated with lung cancer, warning…

New: Discover the “Selected Item” Rubric

New: Discover the “Selected Item” Rubric

GECP has just launched another digital initiative that aims to promote regular scientific updating and the sharing of ideas among peers. It is entitled “Selected Article” and gives voice to the members of the Scientific Committee of the GECP, inviting…

P U B L I C A T I O N S

HOT TOPICS

“ASSOCIAÇÕES DE IMUNOTERAPIA EM DOENTES CPNPC EM ESTADIO IV”

New Therapeutic Approaches

2 1 Y E A R S O F H I S T O R Y I N P E R S P E C T I V E

2000

FOUNDED IN

204

MEMBERS

10

STUDIES

41

CENTROS ASSOCIATES

S U P P O R T

©2022 Copyright GECP